Teva (TEVA) Q2 2026 Earnings Call Transcript

Teva reported Q2 2026 revenue of $4.1B (down 1% YoY in USD) but with strong growth in innovative products: AUSTEDO +40% YoY (to $696M in local currency), AJOVY +56% YoY (to $244M), and UZEDY +43% YoY (to $77M). Free cash flow rose 31% YoY to $622M, and the company raised full-year revenue guidance by $75M at the midpoint to $16.5B–$16.85B, while operating margin is on track toward a 30% target by 2027 as net debt was $12.9B (2.8x net debt/EBITDA). Teva also highlighted a potential U.S. launch for olanzapine LAI in Q4 2026 and confirmed Fitch’s upgrade to investment grade, while warning AUSTEDO Q4 revenue is expected down YoY ahead of IRA-related purchasing/pricing normalization.

Analysis

The equity setup is more about multiple durability than the quarter itself. Teva is proving the old generics drag can be offset by a small number of high-margin assets, but that also means the stock is increasingly a franchise-duration story: if the next 2-3 launches land, the debt overhang and valuation discount should compress; if they slip, the market will quickly re-rate it back toward a leveraged generic house.

Near term, the cleanest risk is not operating execution but policy/flow timing. The market may be underestimating how much of AUSTEDO’s 2026-2027 path depends on payer behavior around the new Medicare price regime and inventory normalization; that creates a visible air pocket in Q4 and a noisy comparison base into early 2027. A bad read-through would hit TEVA harder than the headline numbers suggest because the stock has started to price in a smoother transition to innovative mix.

Second-order winners are the commercial and credit narratives: better cash conversion plus IG status lowers the equity risk premium, and any ordinary-share conversion/index inclusion could create passive demand. The contrarian miss is that management is still asking investors to underwrite multiple pipeline catalysts before any of them are fully de-risked; this is a good business, but not yet a clean annuity. On balance, the move looks constructive but not immune to disappointment if launch cadence or reimbursement data disappoint over the next 1-2 quarters.

Key Decisions for Investors

• Long TEVA on post-earnings weakness, using a 3-6 month horizon to play innovation mix, IG re-rating, and ordinary-share listing flow; cut if Q4 AUSTEDO/combined innovative guidance is revised down materially.
• For event-driven upside, buy TEVA Jan/Mar 2027 calls or call spreads to express olanzapine LAI and ecopipam optionality; thesis fails if either FDA timing slips or payer coverage is slower than management implies.
• Do not chase TEVA after a gap-up; wait for a pullback tied to AUSTEDO inventory noise or IRA-related commentary, since that is the likeliest entry window with better asymmetry.
• Watch TEVA credit and equity spread behavior over the next 1-3 months: if leverage trends toward 2.3x ex-acquisition and cash flow holds, add on strength; if net debt/EBITDA stalls above 3x, reduce exposure.